NASHUA, N.H., July 23 /PRNewswire-FirstCall/ -- iCAD, Inc. an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced it has been added to the Russell Microcap(R) Index when the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 22.
iCAD, Inc. offers a range of CAD products to enhance the early identification of cancer. SecondLook(R), approved by the FDA in 2002, provides a computerized second review of both screening and diagnostic mammograms. TotalLook(R), introduced by iCAD at the end of 2005, provides customers with a comprehensive film-to-digital solution making it easier for women’s health centers to transition from film to digital mammography. This technology assists radiologists in comparing breast images year-to-year to detect subtle changes that may be indicative of breast cancer.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. The Company will hold its membership until Russell reconstitutes its indexes in June 2008.
“We are pleased with our inclusion in this index, which reflects our continued positive momentum,” said Ken Ferry, President and CEO of iCAD. “Russell is an industry leader for stock indexes, and we expect our inclusion will generate greater interest in our stock at an institutional investor level.”
The annual reconstitution of Russell indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. The Russell Microcap comprises the lower half of the 4,000 stocks.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com .
For iCAD, contact Darlene Deptula-Hicks, Executive VP and CFO at 603-882-5200 or via email at ddeptula@icadmed.com
For iCAD investor relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at kevin@cameronassoc.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD, Inc.
CONTACT: Darlene Deptula-Hicks, Executive VP and CFO of iCAD, Inc.,+1-603-882-5200, ddeptula@icadmed.com; Investor Relations, Kevin McGrath,of Cameron Associates, for iCAD, Inc., +1-212-245-4577,kevin@cameronassoc.com; or iCAD Public Relations, Wendy Ryan of SchwartzCommunications, for iCAD, Inc., +1-781-684-0770, icad@schwartz-pr.com
Web site: http://www.icadmed.com/
